Study protocol on the role of intestinal microbiota in colorectal cancer treatment: a pathway to personalized medicine 2.0

Pre-clinical and clinical data produce mounting evidence that the microbiota is strongly associated with colorectal carcinogenesis. Dysbiosis may change the course of carcinogenesis as microbial actions seem to impact genetic and epigenetic alterations leading to dysplasia, clonal expansion and malignant transformation. Initiation and promotion of colorectal cancer may result from direct bacterial actions, bacterial metabolites and inflammatory pathways. Newer aspects of microbiota and colorectal cancer include quorum sensing, biofilm formation, sidedness and effects/countereffects of microbiota and probiotics on chemotherapy. In the future, targeting the microbiota will probably be a powerful weapon in the battle against CRC as gut microbiology, genomics and metabolomics promise to uncover important linkages between microbiota and intestinal health.

show abstract

“…Capecitabine and TAS-102 (tipiracil hydrochloride) are both fluoropyrimidines used for systemic treatment in colorectal cancer patients. 162 …”

Section: Chemotherapymentioning

confidence: 99%

Linking Gut Microbiota to Colorectal Cancer

Raskov¹,

Burcharth²,

Pommergaard³

2017

J. Cancer

120

101

View full text Add to dashboard Cite

show abstract

“…[21][22][23][24] With increased application of any method there comes a growing role for some form of standardization. Microbiomics methods are now supporting research, development, and clinical studies of traditional and new treatments including personalized medicine, [25][26][27] as well as an expanding list of non-medical areas of research and commerce, such as oceanography, agriculture, soil sciences and plant pathology to list but a few examples. [28][29][30] The application and impact of microbiomics is increasing rapidly.…”

Section: Resultsmentioning

confidence: 99%

Hospital Microbiomics: Benchmarking from the First Longitudinal Study of Microbiome Dynamics among Patient, Staff and Hospital Habitats

Powell¹

2017

JBMOA

View full text Add to dashboard Cite

“…Terapię skierowaną na cele molekularne stosuje się m.in. w onkologii [6,7], chorobie Leśniowskiego--Crohna [8], łuszczycy i autoimmunologicznych zapaleniach stawów [9,10].…”

Section: Wprowadzenieunclassified

“…Molecular targeted therapies are used in oncology [6,7], Crohn's disease [8], psoriasis, and autoimmune arthritis [9,10].…”

Section: Introductionmentioning

confidence: 99%

Signaling pathways associated with interleukins 12 and 23 and epigenetic mechanism of sequential-specific regulation of expression of related genes by miRNAs as molecular markers for assessing the potential of anti-cytokine therapies

Grabarek¹,

Wcisło‐Dziadecka²,

Mazurek³

2019

View full text Add to dashboard Cite

The molecular targeted therapy is focused on blocking the activity of specific cytokines and the signalling cascades they activate. In the treatment of psoriasis, this type of therapy is based on treatment with anti-tumor necrosis factor drugs, anti-IL-12/23, anti-IL-17, inhibitors of JAK kinases. Interleukins 12 and 23 interact with the receptors to trigger the JAK/STAT signalling pathway, the end products of which are other cytokines, e.g. tumour necrosis factor, IL-17, interferon g. These cytokines affect both IL-12/23 shaping their concentration profile, as well as trigger other signalling paths themselves. Gene expression is regulated by DNA methylation, miRNA molecules and histone protein modifications. The miRNA seems to be a promising model of a molecular marker system. Understanding the interrelationships between individual signalling pathways associated with IL-12 and IL-23 and the role of epigenetic mechanisms to regulate their expression is important for the development and implementation of new diagnostic-therapeutic schemes and the further development of personalized medicine. streszczenie Terapia ukierunkowana molekularnie skoncentrowana jest na blokowaniu aktywności określonych cytokin i aktywowanych przez nie kaskad sygnałowych. W łuszczycy opiera się ona na leczeniu wieloma grupami leków (leki anty-TNF, anty-IL-12/23, anty-IL-17, inhibitory kinaz JAK). Interleukiny 12 i 23 poprzez interakcje z receptorami uruchamiają ścieżkę sygnalizacyjną JAK/STAT, której Review aRticle/Praca Poglądowa signaling pathways associated with interleukins 12 and 23 and epigenetic mechanism of sequential-specific regulation of expression of related genes by mirnAs as molecular markers for assessing the potential of anti-cytokine therapies Ścieżki sygnalizacyjne związane z interleukiną 12 i 23 oraz epigenetyczny mechanizm sekwencyjnie specyficznej regulacji ekspresji związanych z nimi genów przez cząsteczki mirnA jako molekularne markery oceny potencjału terapii antycytokinowych

show abstract

Study protocol on the role of intestinal microbiota in colorectal cancer treatment: a pathway to personalized medicine 2.0

Cited by 26 publications

References 23 publications

Linking Gut Microbiota to Colorectal Cancer

Linking Gut Microbiota to Colorectal Cancer

Hospital Microbiomics: Benchmarking from the First Longitudinal Study of Microbiome Dynamics among Patient, Staff and Hospital Habitats

Signaling pathways associated with interleukins 12 and 23 and epigenetic mechanism of sequential-specific regulation of expression of related genes by miRNAs as molecular markers for assessing the potential of anti-cytokine therapies

Contact Info

Product

Resources

About